Baseline sputum eosinophil + neutrophil subgroups’ clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort

NHLBI SARP 3 Investigators

doi:10.1016/j.jaci.2020.01.039

Baseline sputum eosinophil + neutrophil subgroups’ clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort

NHLBI SARP 3 Investigators

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	222-226
Number of pages	5
Journal	Journal of Allergy and Clinical Immunology
Volume	146
Issue number	1
DOIs	https://doi.org/10.1016/j.jaci.2020.01.039
State	Published - Jul 2020

Access to Document

10.1016/j.jaci.2020.01.039

Cite this

@article{e9e795035e7d4ceb86966de836393a4c,

title = "Baseline sputum eosinophil + neutrophil subgroups{\textquoteright} clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort",

author = "{NHLBI SARP 3 Investigators} and Hastie, {Annette T.} and Mauger, {David T.} and Denlinger, {Loren C.} and Andrea Coverstone and Mario Castro and Serpil Erzurum and Nijar Jarjour and Levy, {Bruce D.} and Meyers, {Deborah A.} and Moore, {Wendy C.} and Brenda Phillips and Wenzel, {Sally E.} and Fahy, {John V.} and Elliot Israel and Bleecker, {Eugene R.} and Allison Crosby-Thompson and Carrie Nettles and Angeles Cinelli and Meghan Le and Joy Lawrence and Donna Liu and Jenelle Mock and Danica Klaus and Gina Crisafi and Regina Smith and Jeff Krings and Rachel Weaver and Daniel Nguyen and Kristin McIntire and Sara Baicker-McKee and Annabelle Charbit and John Trudeau and Heather Floerke and Susan Foster and Brian Rector and Huiqing Yin-Declue and Noel, {Dr Patricia} and Croxton, {Dr Tom} and Smith, {Dr Robert}",

note = "Funding Information: The research by the principal and coprincipal investigators was funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI) Severe Asthma Research Program: E.R.B. (principal investigator [PI], grant no. U10 HL109164), M.C. (PI, grant no. U10 HL109257), J.V.F. (PI, grant no. U10 HL109146), E.I. and B.D.L. (co-PIs, grant no. U10 HL109172), B. M. Gaston, S.C.E., and W. G. Teague (PI and Co-PIs, grant no. U10 HL109250), N.N.J. (PI, U10 HL109168), S.E.W. (PI, U10 HL109152), and D.T.M. (PI, U10 HL109086). Industry partnerships also provided additional support: AstraZeneca, Boehringer Ingelheim, Genetech, GlaxoSmithKline, MedImmune, Novartis, Regeneron, Sanofi, and Teva. Spirometers used in SARP III were provided by nSpire Health (Longmont, Colo).We acknowledge the contributions of the study coordinators (Allison Crosby-Thompson, Carrie Nettles, Angeles Cinelli and Meghan Le, Joy Lawrence, Donna Liu, Jenelle Mock, Danica Klaus and Gina Crisafi, Regina Smith and Jeff Krings, and Rachel Weaver) and laboratory staff (Daniel Nguyen and Kristin McIntire, Sara Baicker-McKee, Annabelle Charbit, John Trudeau, Heather Floerke, Susan Foster and Brian Rector, and Huiqing Yin-Declue) at each of the clinical centers, and the Data Coordinating Center in addition to all the study participants who are integral to the success of the Severe Asthma Research Program. We appreciate the support of the Scientific Program Officers at the National Heart, Lung, and Blood Institute (Dr Patricia Noel, Dr Tom Croxton, and Dr Robert Smith) and input from the members of the Data Safety and Monitoring Board. Funding Information: The research by the principal and coprincipal investigators was funded by the National Institutes of Health / National Heart, Lung, and Blood Institute (NIH/NHLBI) Severe Asthma Research Program: E.R.B. (principal investigator [PI], grant no. U10 HL109164 ), M.C. (PI, grant no. U10 HL109257 ), J.V.F. (PI, grant no. U10 HL109146 ), E.I. and B.D.L. (co-PIs, grant no. U10 HL109172 ), B. M. Gaston., S.C.E., and W. G. Teague (PI and Co-PIs, grant no. U10 HL109250 ), N.N.J. (PI, U10 HL109168 ), S.E.W. (PI, U10 HL109152 ), and D.T.M. (PI, U10 HL109086 ). Industry partnerships also provided additional support: AstraZeneca , Boehringer Ingelheim , Genetech, GlaxoSmithKline , MedImmune , Novartis , Regeneron, Sanofi, and Teva. Spirometers used in SARP III were provided by nSpire Health (Longmont, Colo). ",

year = "2020",

month = jul,

doi = "10.1016/j.jaci.2020.01.039",

language = "English",

volume = "146",

pages = "222--226",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

number = "1",

}

TY - JOUR

T1 - Baseline sputum eosinophil + neutrophil subgroups’ clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort

AU - NHLBI SARP 3 Investigators

AU - Hastie, Annette T.

AU - Mauger, David T.

AU - Denlinger, Loren C.

AU - Coverstone, Andrea

AU - Castro, Mario

AU - Erzurum, Serpil

AU - Jarjour, Nijar

AU - Levy, Bruce D.

AU - Meyers, Deborah A.

AU - Moore, Wendy C.

AU - Phillips, Brenda

AU - Wenzel, Sally E.

AU - Fahy, John V.

AU - Israel, Elliot

AU - Bleecker, Eugene R.

AU - Crosby-Thompson, Allison

AU - Nettles, Carrie

AU - Cinelli, Angeles

AU - Le, Meghan

AU - Lawrence, Joy

AU - Liu, Donna

AU - Mock, Jenelle

AU - Klaus, Danica

AU - Crisafi, Gina

AU - Smith, Regina

AU - Krings, Jeff

AU - Weaver, Rachel

AU - Nguyen, Daniel

AU - McIntire, Kristin

AU - Baicker-McKee, Sara

AU - Charbit, Annabelle

AU - Trudeau, John

AU - Floerke, Heather

AU - Foster, Susan

AU - Rector, Brian

AU - Yin-Declue, Huiqing

AU - Noel, Dr Patricia

AU - Croxton, Dr Tom

AU - Smith, Dr Robert

N1 - Funding Information: The research by the principal and coprincipal investigators was funded by the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI) Severe Asthma Research Program: E.R.B. (principal investigator [PI], grant no. U10 HL109164), M.C. (PI, grant no. U10 HL109257), J.V.F. (PI, grant no. U10 HL109146), E.I. and B.D.L. (co-PIs, grant no. U10 HL109172), B. M. Gaston, S.C.E., and W. G. Teague (PI and Co-PIs, grant no. U10 HL109250), N.N.J. (PI, U10 HL109168), S.E.W. (PI, U10 HL109152), and D.T.M. (PI, U10 HL109086). Industry partnerships also provided additional support: AstraZeneca, Boehringer Ingelheim, Genetech, GlaxoSmithKline, MedImmune, Novartis, Regeneron, Sanofi, and Teva. Spirometers used in SARP III were provided by nSpire Health (Longmont, Colo).We acknowledge the contributions of the study coordinators (Allison Crosby-Thompson, Carrie Nettles, Angeles Cinelli and Meghan Le, Joy Lawrence, Donna Liu, Jenelle Mock, Danica Klaus and Gina Crisafi, Regina Smith and Jeff Krings, and Rachel Weaver) and laboratory staff (Daniel Nguyen and Kristin McIntire, Sara Baicker-McKee, Annabelle Charbit, John Trudeau, Heather Floerke, Susan Foster and Brian Rector, and Huiqing Yin-Declue) at each of the clinical centers, and the Data Coordinating Center in addition to all the study participants who are integral to the success of the Severe Asthma Research Program. We appreciate the support of the Scientific Program Officers at the National Heart, Lung, and Blood Institute (Dr Patricia Noel, Dr Tom Croxton, and Dr Robert Smith) and input from the members of the Data Safety and Monitoring Board. Funding Information: The research by the principal and coprincipal investigators was funded by the National Institutes of Health / National Heart, Lung, and Blood Institute (NIH/NHLBI) Severe Asthma Research Program: E.R.B. (principal investigator [PI], grant no. U10 HL109164 ), M.C. (PI, grant no. U10 HL109257 ), J.V.F. (PI, grant no. U10 HL109146 ), E.I. and B.D.L. (co-PIs, grant no. U10 HL109172 ), B. M. Gaston., S.C.E., and W. G. Teague (PI and Co-PIs, grant no. U10 HL109250 ), N.N.J. (PI, U10 HL109168 ), S.E.W. (PI, U10 HL109152 ), and D.T.M. (PI, U10 HL109086 ). Industry partnerships also provided additional support: AstraZeneca , Boehringer Ingelheim , Genetech, GlaxoSmithKline , MedImmune , Novartis , Regeneron, Sanofi, and Teva. Spirometers used in SARP III were provided by nSpire Health (Longmont, Colo).

PY - 2020/7

Y1 - 2020/7

UR - http://www.scopus.com/inward/record.url?scp=85081909518&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2020.01.039

DO - 10.1016/j.jaci.2020.01.039

M3 - Article

C2 - 32032631

AN - SCOPUS:85081909518

SN - 0091-6749

VL - 146

SP - 222

EP - 226

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 1

ER -

Baseline sputum eosinophil + neutrophil subgroups’ clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort

Access to Document

Other files and links

Cite this